

## Anti-GP6/Glycoprotein-6 Antibody (Glenzocimab)

### Introduction

Glenzocimab (ACT017) is a Fab fragment of a humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential to be used in the study of acute ischemic stroke.

### Product parameters

Alternative Names	ACT017, 9O12.2
Target Accession	Q9HCN6
Target	GP6 / Glycoprotein-6
CAS number	2101829-58-5
Molecular Weight	48.29 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.



### **APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

